“It is very pleasing to observe a high interest in what Iconovo has to offer and it’s satisfactory to see results from our intense business development efforts, aiming to initiate more collaborations with some of the world’s leading pharma companies,” says Roger Lassing, VP Business Development

Iconovo has successfully expanded its CDMO business performing contract development of original drugs in the company's inhaler platforms where Iconovo receives a fixed, healthy profit margin on work performed. Iconovo already has five active customer agreements in the CDMO area and is expected to add three to five new agreements per year. In the coming years, this area will constitute a significant part of the revenue. An important factor for the company's long-term value creation is that new and existing customer agreements in this area also have the potential to lead to license agreements or inhaler sales.

"We look forward with excitement to collaborating with one of the leading pharmaceutical companies in the world. This further validates that Iconovo offers world-class inhalers that also the largest and most successful companies want to test and potentially use in their development of new inhalation products. There are no guarantees that the company will choose Iconovo's multidose inhaler after the evaluation, but we believe in our product," says Johan Wäborg, CEO of Iconovo